Tonix Pharmaceuticals Broke Ground in Hamilton

The pharmaceutical company has begun construction on a new production facility on a 44-acre plot of land.

Updated on Oct. 9, 2026 in Manufacturing

Tonix Pharmaceuticals Broke Ground in Hamilton

Live Poll

Do you believe biotech expansion is a reliable way to improve your local economy?

Tonix Pharmaceuticals held a groundbreaking ceremony for a new manufacturing facility in Hamilton, Montana. The site is intended to expand the domestic infrastructure for infectious disease treatments.

Why it matters

The project represents a strategic move for the company to expand its presence within the Bitterroot biotech corridor. This development aims to enhance capacity for specialized medical production.

The company, which was founded 17 years ago, is developing a site that spans 44 acres of Targeted Economic Development District land.

The players

Tonix Pharmaceuticals

This is a pharmaceutical firm that has been operating for 17 years and is now establishing a new manufacturing base in Montana.

The details

The facility will be dedicated to the initial production of TNX 4800, a prophylactic designed to combat Lyme disease. This project reflects the company's broader objective to strengthen its domestic infrastructure for the treatment of infectious diseases.

Tonix Pharmaceuticals was founded 17 years ago.
The groundbreaking ceremony took place on October 8, 2026.
Construction is expected to take a few years to complete in the future.

Market Landscape

The establishment of this manufacturing site contributes to the ongoing expansion of the Bitterroot biotech corridor. This move positions the firm alongside other regional entities like the nearby Rocky Mountain Labs to consolidate biotech operations in the area.

Residents in the area may see a long-term shift in the local job market as the company builds out its infrastructure. The facility's focus on prophylactic production for Lyme disease could also impact future public health options available in the region.

The takeaway

This expansion signals a localized commitment to increasing the domestic supply of specialized medical treatments. Companies often choose sites within established biotech corridors to leverage existing regional expertise and infrastructure.